
Opinion|Videos|July 11, 2024
Clinical Utilization of TROP2-Directed Antibody-Drug Conjugates
Author(s)Aditya Bardia, MD, MPH, Laura Huppert, MD
Medical oncologists share clinical practices for selecting and sequencing TROP2-directed antibody-drug conjugates, highlighting ideal candidates for sacituzumab govitecan or datopotamab deruxtecan.
Advertisement
Episodes in this series

Video content above is prompted by the following question:
- What insights and perspectives can you provide on the use of TROP2-directed antibody-drug conjugates from your practice?
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Dr Cloughesy on Extended Follow-Up Data for Vorasidenib in IDH1/2 Mutant Glioma
2
Bispecific ADC Iza-Bren Extends Survival in Advanced TNBC
3
ASCO 2026 GU Cancer Highlights: Beyond the LBAs
4
FDA Grants Priority Review to Giredestrant for ER+/HER2- Breast Cancer
5



































